KOL Views: How strong is Array’s case for making bini/enco a gold standard in colorectal cancer?

Array BioPharma and partner Pierre Fabre reported updated Phase III BEACON CRC data suggesting that binimetinib/encorafenib (bini/enco) added to anti-EGFR mAb cetuximab is performing significantly better than all other options in patients with BRAF-mutant colorectal cancer. (See ViewPoints: Array takes big step towards bigger riches with bini/enco.)

To provide FirstWord readers with rapid feedback on what hurdles remain and how quickly bini/enco is set to change practice patterns in colorectal cancer, we are hosting an expert call with a key opinion leader (KOL) this week.

Key topics that will be discussed during the call include, among other things…how is BRAF-mutant colorectal cancer treated currently; how impressive are the interim BEACON CRC results, and what is your level of confidence that bini/enco’s performance will remain strong; what are the biggest unanswered questions about use of the regimen in colorectal cancer; might the recent addition of a triple combination involving Roche/Genentech’s Zelboraf (vemurafenib) to the National Comprehensive Cancer Network (NCCN) guidelines hamper bini/enco’s adoption; what are you expectations for moving bini/enco beyond relapsed/refractory patients into the front-line setting?

Ask the expert!

Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the evolving treatment paradigm in BRAF-mutant colorectal cancer.

We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.

To ensure access to all KOL Views content, click here to upgrade your FirstWord Pharma service or contact us to discuss your market intelligence needs.

As always, FirstWord would very much like to receive your feedback and suggestions.

To read more KOL Views articles, click here.